Abstract
Background and aim:
Dementia is a disease associated with cognitive and/or behavioral changes that interfere with the ability to perform daily activities. Alzheimer’s disease is the most common type of dementia. The aim of this mini-review is to summarize all the syndromes characterized by dementia and for which the associated gene is known.
Methods:
We searched those syndromes in PubMed and OMIM database.
Results:
Two forms of dementia exist: the multifactorial dementia results from the interaction of different genetic and environmental factors, the hereditary dementia associated with a single gene. Individuals with a family history of dementia and early onset of the disease are more likely to have a hereditary form of dementia. Dementias are mainly autosomal dominant, but they can also be autosomal recessive or X-linked.
Conclusions:
Since dementia has high clinical and genetic heterogeneity, the use in diagnostics of a large panel of genes may greatly help to speed up the determination of the molecular diagnosis and/or establish a risk of recurrence in family members for the purpose of planning appropriate preventive and/or therapeutic measures. (www.actabiomedica.it)
Keywords: Mendelian dementia, Alzheimer disease, Parkinson disease
Dementia is a disease associated with cognitive and/or behavioral changes that interfere with the ability to perform daily activities (1). Dementia occurs in 5-7% of individuals over 60 years of age (2). Alzheimer’s disease (AD) is the most common type of dementia (about 60-80% of cases), of which <10% have early onset. It is familial in 25% cases (3) and is a degenerative dementia characterized by cortical disorders such as agnosia, aphasia and apraxia. Other degenerative dementias are frontotemporal dementia (Pick’s disease, primary progressive aphasia, semantic dementia), progressive supranuclear paralysis, Lewy’s body dementia, Parkinson’s dementia, Huntington’s disease, prion disease and cortical-basal degeneration. There are also reversible dementias and vascular dementias (4,5). Pharmacological treatment is supportive. Diagnosis of dementias involves neurological examination, including mental status examination, neuropsychological evaluation, laboratory tests and neuroimaging. The differential diagnosis of Alzheimer’s disease includes other causes of dementia, particularly treatable forms of cognitive decline that include depression, chronic drug intoxication, chronic central nervous system infection, thyroid disease, vitamin deficiencies, inflammatory central nervous system angioitis and normal pressure hydrocephalus. A distinction must also be made between different forms of dementia (3). Multifactorial forms of dementia, resulting from the interaction of different genetic and environmental factors, and hereditary forms of dementia are known (6). Individuals with a family history of dementia and early onset of the disease are more likely to have a hereditary form of dementia (1). Dementias are mainly autosomal dominant, but they can also be inherited in an autosomal recessive or X-linked manner (Table 1). Reference guidelines for genetic testing are contained in “Genetics Home Reference” (ghr.nlm.nih.gov) and Gene Reviews (3). Detection of variations in the genes in Table 1 is based on analysis of a multi-gene panel by next generation sequencing of the coding regions and their intron-exon junctions. Testing aims to identify variants in genes known to be associated with dementia in subjects suspected to have Mendelian dementia.
Table 1.
Syndromes characterized by dementia for which the genetic basis is known
| Gene | OMIM# Gene | Inheritance | Phenotype | OMIM# Phenotype/Reference | Gene function (https://www.genecards.org/) |
| APOE | 107741 | ADo | AD2 | 104310 | Essential for catabolism of triglyceride-rich lipoproteins |
| APP | 104760 | ADo | AD | 104300 | Neurite growth, neuronal adhesion, axonogenesis, synaptogenesis |
| C9orf72 | 614260 | ADo | FTDALS1 | 105550 | Regulation of endosomal trafficking, autophagy |
| CHMP2B | 609512 | ADo | FTD3 | 600795 | Involved in recycling/degradation of growth factor receptors, lysosomal enzymes, lipids |
| CSF1R | 164770 | ADo | HDLS | 221820 | Cytokine controlling macrophages production, differentiation, function |
| DCTN1 | 601143 | ADo | Perry syndrome | 168605 | Endoplasmic reticulum-to-Golgi transport, movement of lysosomes/endosomes, spindle formation, chromosome movement, nuclear positioning, axonogenesis |
| FUS | 137070 | ADo, AR | ALS6 | 608030 | Crucial for dendritic spine formation/stability, RNA transport/stability, synaptic homeostasis |
| GRN | 138945 | ADo | Frontotemporal lobar degeneration with TDP43 inclusions | 607485 | Inflammation modulation in neurons by preserving neuron survival, axonal outgrowth, neuronal integrity |
| MAPT | 157140 | ADo | FTD, Pick disease of brain | 600274, 172700 | Neuronal polarity establishment/maintenance |
| PRNP | 176640 | ADo | HDL1, spongiform encephalopathy with neuropsychiatric features | 603218, 606688 | Neuronal development, synaptic plasticity. Required for neuronal myelin sheath maintenance |
| PSEN1 | 104311 | ADo | AD, FTD | 607822, 600274 | Regulation of neurite outgrowth, presynaptic facilitation, spike transmission, synaptic vesicles replenishment |
| PSEN2 | 600759 | ADo | Alzheimer disease-4 | 606889 | Modulation of Ca2+ ion shuttling between endoplasmic reticulum and mitochondria |
| SIGMAR1 | 601978 | ADo | Frontotemporal lobar degeneration-motor neuron disease | (7) | Necessary for axonal retrograde movement of mitochondria in motor neurons |
| SORL1 | 602005 | ADo | Late-onset AD | / | Positive regulation of BDNF signaling |
| SQSTM1 | 601530 | ADo | FTDALS3 | 616437 | Formation/degradation of ubiquitin-containing inclusions, involved in cell differentiation, apoptosis, immune response, regulation of K+ channels |
| TARDBP | 605078 | ADo | ALS10 | 612069 | Splicing regulation of mRNAs encoding proteins involved in neuronal survival |
| TREM2 | 605086 | AD | PLOSL2 | 618193 | Regulation of microglial proliferation, chemotaxis, outgrowth, activation and phagocytosis of apoptotic neurons and myelin debris, neuronal synapses during brain development |
| TYROBP | 604142 | AR | PLOSL1 | 221770 | Promotion of neuronal apoptosis during brain development and proinflammatory responses in microglia after nerve injury |
| UBQLN2 | 300264 | XLD | ALS15 | 300857 | Regulation of ubiquitin-proteasome system, autophagy, endoplasmic reticulum-associated protein degradation pathways |
| VCP | 601023 | ADo | IBMPFD1 | 167320 | Ubiquitin-dependent sorting of membrane proteins to lysosomes |
AD = Alzheimer’s dis ease; Ado = autosomal dominant; FTDALS = frontotemporal dementia and/or amyotrophic lateral sclerosis; FTD = frontotemporal dementia; HDLS = hereditary diffuse leukoencephalopathy with spheroids; ALS = amyotrophic lateral sclerosis with/without frontotemporal dementia; HDL = Huntington disease-like; PLOSL = polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy; IBMPFD = inclusion body myopathy with early-onset Paget disease with/without frontotemporal dementia.
Our NGS test has an analytical sensitivity and specificity ≥99%. On the other hand, diagnostic sensitivity in individuals with early-onset familial Alzheimer’s disease with a pathogenic variant in APP, PSEN1 or PSEN2 can be identified in 40-80% of cases (8). A pathogenic variant can be identified in about 65% of cases of frontotemporal dementia (9). A genetic cause can be identified in about 10-15% of cases of prion disease (10). The diagnostic specificity of Alzheimer’s disease is about 70% (11).
Although dementia has high clinical and genetic heterogeneity, our test makes it possible to determine the molecular diagnosis of new subjects and/or establish a risk of recurrence in family members for the purpose of planning appropriate preventive and/or therapeutic measures.
Conflict of interest:
Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article
References
- 1.Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. Lancet. 2014;383:828–40. doi: 10.1016/S0140-6736(13)60630-3. [DOI] [PubMed] [Google Scholar]
- 2.Wszolek Z, Konno T. Perry syndrome. GeneReviews. 2010 Available at: https://www.ncbi.nlm.nih.gov/books/NBK47027/ [Google Scholar]
- 3.Bird TD. Alzheimer disease overview. GeneReviews. 1998 Available at: https://www.ncbi.nlm.nih.gov/books/NBK1161/ [Google Scholar]
- 4.Kitagaki H, Mori E, Ishii K, Yamaji S, Hirono N, Imamura T. CSF spaces in idiopathic normal pressure hydrocephalus: morphology and volumetry. AJNR Am J Neuroradiol. 1998;19:1277–84. [PMC free article] [PubMed] [Google Scholar]
- 5.Barker W, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida brain bank Alzheimer. Dis Assoc Disord. 2002;16:203–12. doi: 10.1097/00002093-200210000-00001. [DOI] [PubMed] [Google Scholar]
- 6.Fenoglio C, Scarpini E, Serpente M, Galimberti D. Role of genetics and epigenetics in the pathogenesis of Alzheimer’s disease and frontotemporal dementia. J Alzheimers Dis. 2018;62:913–32. doi: 10.3233/JAD-170702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Luty AA, Kwok JB, Dobson-Stone C, et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol. 2010;68:639–49. doi: 10.1002/ana.22274. [DOI] [PubMed] [Google Scholar]
- 8.Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer’s disease: mutation frequency in 31 families. Neurology. 2003;60:235–9. doi: 10.1212/01.wnl.0000042088.22694.e3. [DOI] [PubMed] [Google Scholar]
- 9.Olszewska DA, Lonergan R, Fallon EM, Lynch T. Genetics of frontotemporal dementia. Curr Neurol Neurosci Rep. 2016;16:107. doi: 10.1007/s11910-016-0707-9. [DOI] [PubMed] [Google Scholar]
- 10.Mackenzie G, Will R. Creutzfeldt-Jakob disease: recent developments. F1000Res. 2017;6:2053. doi: 10.12688/f1000research.12681.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Nicolas G, Wallon D, Charbonnier C, et al. Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. Eur J Hum Genet. 2016;24:710–6. doi: 10.1038/ejhg.2015.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
